Novo Nordisk is a global healthcare company focusing on diabetes care, growth hormone treatment and haemostasis management. Under the concept of the “Triple Bottom Line”, Novo Nordisk is committed to social and environmental responsibility in addition to being an economically viable enterprise.
In Japan, Novo Nordisk Pharma Ltd. started business in 1980, and since then, we have been contributing to society by providing superior products and services which satisfy real needs and improve the quality of people’s lives. In 2006, we initiated an activity called “changing diabetes,” aiming to improve awareness, the care and the treatment of diabetes.